Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc has demonstrated significant growth in its business operations, highlighted by a remarkable 41% increase in VTE procedure volumes during December, marking its highest monthly performance to date. Additionally, the company's non-GAAP operating margin improved by 200 basis points year-over-year, driven by enhanced gross margins and reduced R&D expenses, reflecting operational efficiency. The overall sales figures for Thrombectomy and E&A segments also show upward trends, with Thrombectomy sales reaching $222.7 million, a 16.9% growth, and E&A sales increasing by 5.1%, indicative of strong market demand and effective product mix management.
Bears say
The financial analyst highlights significant concerns regarding Penumbra Inc.'s outlook, primarily driven by anticipated revenue growth decreasing to below 12% due to weaker-than-expected contributions from new products and sluggish profitability improvements. Notably, adjustments to revenue estimates for 2025 and 2026 reflect a downward revision, projecting revenues at $1.349 billion and $1.531 billion, respectively, illustrating a cautious adjustment in response to market challenges. Additionally, risks such as competitive pressures, potential supply chain disruptions, and the impact of COVID-19 variants further compound the negative sentiment surrounding the company’s financial performance and future growth prospects.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares